New drug cocktail shows promise against tough cancers
NCT ID NCT02499328
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested combinations of the immunotherapy drug durvalumab with other drugs (danvatirsen, AZD5069, or tremelimumab) in 340 adults with advanced solid tumors or head and neck cancer. The goal was to find safe doses and see if the combinations shrink tumors. The trial has completed, and results may help design future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (MEDI4736), danvatirsen (AZD9150), AZD5069, and tremelimumab
What this could lead to
If successful, this could point toward a new combination treatment option for advanced head and neck cancer.
What could go wrong
This is an early-phase trial (Phase 1b/2) with a small number of participants, so results may not apply to all patients. Side effects from combining multiple drugs are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS & METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Birmingham, Alabama, 35294, United States
-
Research Site
Duarte, California, 91010, United States
-
Research Site
La Jolla, California, 92093, United States
-
Research Site
Los Angeles, California, 90024, United States
-
Research Site
Los Angeles, California, 90089, United States
-
Research Site
Orange, California, 92868-3298, United States
-
Research Site
San Francisco, California, 94158, United States
-
Research Site
Denver, Colorado, 80218, United States
-
Research Site
Plantation, Florida, 33324, United States
-
Research Site
Sarasota, Florida, 34232, United States
-
Research Site
Lafayette, Indiana, 47905, United States
-
Research Site
Boston, Massachusetts, 02111, United States
-
Research Site
Detroit, Michigan, 48201, United States
-
Research Site
Billings, Montana, 59101, United States
-
Research Site
Morristown, New Jersey, 07960, United States
-
Research Site
Cincinnati, Ohio, 45267-2827, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Fairfax, Virginia, 22031, United States
-
Research Site
Seattle, Washington, 98109, United States
-
Research Site
Antwerp, 2020, Belgium
-
Research Site
Brussels, 1000, Belgium
-
Research Site
Brussels, 1200, Belgium
-
Research Site
Edegem, 2650, Belgium
-
Research Site
Namur, 5000, Belgium
-
Research Site
Berlin, 12200, Germany
-
Research Site
Cologne, 50670, Germany
-
Research Site
Dresden, 1307, Germany
-
Research Site
Frankfurt, 60488, Germany
-
Research Site
Hamburg, 20246, Germany
-
Research Site
Hanover, 30625, Germany
-
Research Site
Jena, 07743, Germany
-
Research Site
München, 81675, Germany
-
Research Site
Milan, 20133, Italy
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Hospitalet deLlobregat, 08907, Spain
-
Research Site
Madrid, 28040, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Toledo, 45004, Spain
-
Research Site
Birmingham, B15 2TH, United Kingdom
-
Research Site
London, SE1 9RT, United Kingdom
-
Research Site
London, SW3 6JB, United Kingdom
-
Research Site
Manchester, M20 4BX, United Kingdom
-
Research Site
Surrey, SM2 5PT, United Kingdom
-
Research Site
Taunton, TA1 5DA, United Kingdom